BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone415-506-6700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.49 billion
Profitability
Miscellaneous
Employees2,849
Next Earnings Date2/20/2020 (Estimated)
OptionableOptionable
BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions
What is BioMarin Pharmaceutical's stock symbol?
BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."
How were BioMarin Pharmaceutical's earnings last quarter?
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its earnings results on Wednesday, October, 23rd. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.25. The biotechnology company had revenue of $461.10 million for the quarter, compared to analyst estimates of $455.78 million. BioMarin Pharmaceutical had a negative return on equity of 1.35% and a negative net margin of 2.65%. BioMarin Pharmaceutical's revenue was up 17.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.07) earnings per share. View BioMarin Pharmaceutical's Earnings History.
When is BioMarin Pharmaceutical's next earnings date?
What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?
BioMarin Pharmaceutical issued an update on its FY 2019 earnings guidance on Wednesday, October, 23rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.69-1.72 billion, compared to the consensus revenue estimate of $1.7 billion.
What price target have analysts set for BMRN?
17 Wall Street analysts have issued 12 month target prices for BioMarin Pharmaceutical's stock. Their forecasts range from $77.00 to $152.00. On average, they anticipate BioMarin Pharmaceutical's share price to reach $108.50 in the next year. This suggests a possible upside of 40.8% from the stock's current price. View Analyst Price Targets for BioMarin Pharmaceutical.
What is the consensus analysts' recommendation for BioMarin Pharmaceutical?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioMarin Pharmaceutical.
What are Wall Street analysts saying about BioMarin Pharmaceutical stock?
Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock:
- 1. According to Zacks Investment Research, "BioMarin beat estimates for earnings and sales in Q3. Sales of BioMarin’s key orphan disease drugs – Vimizim and Kuvan – are being driven by strong demand trends. Its newest product, Palynziq is witnessing strong commercial uptake in the United States. BioMarin’s rare disease pipeline is progressing well. The company targets regulatory filings for Valrox by year-end and vosoritide in 2020. Growing pipeline focus on gene therapy agents is encouraging. Valrox, a gene therapy for hemophilia A, is anticipated to be transformational, if approved. However, any development setbacks related to its pipeline candidates can hurt the stock. Moreover, uneven quarterly product sales of Naglazyme and Vimzin, owing to infrequent ordering patterns in some ex-U.S. countries, are a concern. The stock has underperformed the industry this year. " (11/6/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our OW and $131 PT. We continue to see highly favorable risk/reward ahead of key pipeline updates over the next 12 months. BioMarin reported an in-line quarter, although the overwhelming focus of the call was on valrox (hemophilia A gene therapy). The valrox 3-year update is on track for a top-line by early June (ISTH late-breaker submission due June 7). Not much new color on valrox from the call: management continues to sound confident in durability and potential for accelerated pathway (BMRN’s filing decision by YE19). For investors, we think valrox is more of a show-me story, which is why the update in June is important, although at this point somewhat of an overhang, in our view." (4/26/2019)
Has BioMarin Pharmaceutical been receiving favorable news coverage?
News headlines about BMRN stock have trended positive this week, InfoTrie reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BioMarin Pharmaceutical earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for BioMarin Pharmaceutical.
Are investors shorting BioMarin Pharmaceutical?
BioMarin Pharmaceutical saw a drop in short interest in October. As of October 15th, there was short interest totalling 7,580,000 shares, a drop of 8.7% from the September 15th total of 8,300,000 shares. Based on an average daily trading volume, of 1,320,000 shares, the short-interest ratio is presently 5.7 days. Currently, 4.3% of the shares of the stock are short sold. View BioMarin Pharmaceutical's Current Options Chain.
Who are some of BioMarin Pharmaceutical's key competitors?
Some companies that are related to BioMarin Pharmaceutical include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).
What other stocks do shareholders of BioMarin Pharmaceutical own?
Who are BioMarin Pharmaceutical's key executives?
BioMarin Pharmaceutical's management team includes the folowing people:
- Mr. Jean-Jacques Bienaimé M.B.A., MBA, Chairman & CEO (Age 66)
- Mr. Daniel K. Spiegelman, Exec. VP & CFO (Age 60)
- Dr. Robert A. Baffi, Exec. VP of Technical Operations (Age 64)
- Mr. Jeffrey Robert Ajer, Exec. VP & Chief Commercial Officer (Age 57)
- Dr. Henry J. Fuchs, Pres of Worldwide R&D (Age 61)
Who are BioMarin Pharmaceutical's major shareholders?
BioMarin Pharmaceutical's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include First Trust Advisors LP (0.48%), Manning & Napier Group LLC (0.41%), Sumitomo Mitsui Trust Holdings Inc. (0.37%), California Public Employees Retirement System (0.19%), Rhenman & Partners Asset Management AB (0.16%) and Torray LLC (0.11%). Company insiders that own BioMarin Pharmaceutical stock include Alan Lewis, Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Richard A Meier, Robert Baffi and V Bryan Lawlis. View Institutional Ownership Trends for BioMarin Pharmaceutical.
Which institutional investors are selling BioMarin Pharmaceutical stock?
BMRN stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Massachusetts Financial Services Co. MA, Nisa Investment Advisors LLC, Eqis Capital Management Inc., Sumitomo Mitsui Trust Holdings Inc., Commonwealth Equity Services LLC, Wealthstreet Investment Advisors LLC and Schmidt P J Investment Management Inc.. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include Brian Mueller, Daniel K Spiegelman, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer and V Bryan Lawlis. View Insider Buying and Selling for BioMarin Pharmaceutical.
Which institutional investors are buying BioMarin Pharmaceutical stock?
BMRN stock was acquired by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, California Public Employees Retirement System, Public Employees Retirement Association of Colorado, CMH Wealth Management LLC, Comgest Global Investors S.A.S., Brinker Capital Inc., Fjarde AP Fonden Fourth Swedish National Pension Fund and Rhenman & Partners Asset Management AB. View Insider Buying and Selling for BioMarin Pharmaceutical.
How do I buy shares of BioMarin Pharmaceutical?
Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is BioMarin Pharmaceutical's stock price today?
One share of BMRN stock can currently be purchased for approximately $77.07.
How big of a company is BioMarin Pharmaceutical?
BioMarin Pharmaceutical has a market capitalization of $13.84 billion and generates $1.49 billion in revenue each year. The biotechnology company earns $-77,210,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. BioMarin Pharmaceutical employs 2,849 workers across the globe.View Additional Information About BioMarin Pharmaceutical.
What is BioMarin Pharmaceutical's official website?
How can I contact BioMarin Pharmaceutical?
BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected]
MarketBeat Community Rating for BioMarin Pharmaceutical (NASDAQ BMRN)
MarketBeat's community ratings are surveys of what our community members think about BioMarin Pharmaceutical and other stocks. Vote "Outperform" if you believe BMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
